Nano-enabled solutions against viral infections like COVID-19

Report reference B0700
Latest version v00 (July 2020)
Report length 28 Pages
12 Figures
Report Format PDF Preview PDF
Report Price 276 British Pounds

Key topics Covered

Nanomedicine and Vaccines and Nanovaccines
Diagnosis: Point of Care tests
Masks and Respirators
HEPA filters
Antiviral coatings
Antiviral bulk materials
Personal hygiene and disinfectants
Relevant terminology
Applicable Standards
B0700 Report
Preview PDF

Email for report delivery:

This document was created to address a number of questions from the community about how nanotechnology and nanomaterials may be (or indeed are already) helping to fight viral infections like Coronavirus (2019-nCoV). This document analyses relevant nanotechnological developments to address virus detection, prevention, protection, mitigation and control measures.
This document is particularly relevant to innovators, researchers, policy makers and funding managers. Impact on various technology markets due to COVID-19 was estimated. Market size for nanovaccines, COVID-19 tests, protective masks, disinfectants, coatings and HEPA air filters were evaluated.

Report Structure

Terms of usage
1. Introduction
2. Applications
2.1. Nanomedicine and Vaccines
2.1.1. Industry developments
2.1.2. Market information
2.2. Diagnosis: Point of Care tests
2.2.1. Industry advances
2.2.2. Scientific advances
2.2.3. Market Information
2.3. Masks and Respirators
2.3.1. Market Information
2.3.2. Industrial Activity
2.3.3. Scientific Advances
2.4. HEPA filters
2.4.1. Market Information
2.5. Antiviral coatings
2.5.1. Biocidal Release coatings
2.5.2. Active contact surface
2.5.3. Antiadhesive coating
2.5.4. Thermally or mechanically activated release coating
2.5.5. Topographically frustrating coating
2.5.6. Market Information
2.6. Antiviral bulk materials
2.6.1. Market Information
2.7. Personal hygiene
2.7.1. Market Information
3. Useful definitions
4. Useful Standards
5. Index
Annex A Not nano-related breakthroughs in vaccine development for COVID-19
6. References

Report Price and license

This report was prepared by BREC Solutions and its global partners. The purchase of this document implies the buying of license for single (individual) use. BREC Solutions reports license entitles the user to receive updates as new versions for the duration of one year (12 calendar months after that day of purchase). Access to update after that 12-month period require a new purchase of the license.

The user is not allowed to share or sell this document as the license does not imply ownership. BREC Solutions is the only owner of this material. The user is allowed to share this document with colleagues in the same organization provided that they in turn are not disclosing it externally. Permission for the use of data, diagram or findings may be granted to active license holder to use in other publications that would reference this report (by title, report number, publisher and year). Further information can be obtained from